SEATTLE and SOUTH SAN FRANCISCO, Calif., March 10, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today reported financial results and a corporate update for the fourth quarter and full year ended December 31, 2015.
Corporate Update and Recent Highlights
New positive data support continued development of Immune Design’s wholly-owned immuno-oncology product candidates.
Corporate Update and Recent Highlights
New positive data support continued development of Immune Design’s wholly-owned immuno-oncology product candidates.
